A gene therapy which offers "meaningful improvements" to the vision of an inherited retinal disease could be given US Food and Drug Administration approval by October, following unanimous endorsement by an advisory panel in January 2018. Early results of a study of the therapy, published in The Lancet, revealed 93% of participants suffering with rare inherited retinal disease Leber congenital amaurosis experienced improved vision after treatment. Medics leading the study hope it could open the door to future therapies for other ocular conditions.
A gene therapy which offers "meaningful improvements" to the vision of an inherited retinal disease could be given US Food and Drug Administration approval by January 2018, following unanimous endorsement by an advisory panel in October. Early results of a study of the therapy, published in The Lancet, revealed 93% of participants suffering with rare inherited retinal disease Leber congenital amaurosis experienced improved vision after treatment. Medics leading the study hope it could open the door to future therapies for other ocular conditions.